Ardsley Advisory Partners’s Viking Therapeutics VKTX Stock Holding History

Ardsley Advisory Partners’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,000	Closed	-$174K	–	159
2018 Q3	$174K	Sell	10,000 -25,000	-71%	-$298K	0.02%	142
2018 Q2	$332K	Buy	+35,000	New	+$233K	0.05%	133

Other funds holding VKTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Ardsley Advisory Partners's VKTX Position: Q4 2018 in Review

Ardsley Advisory Partners sold out of Viking Therapeutics (VKTX) in Q4 2018, closing a stake of 10,000 shares — an estimated $174K sold.

Ardsley Advisory Partners first reported a position in VKTX in Q2 2018 and held it in 2 quarters. The position peaked at $332K in Q2 2018. 168 funds tracked by Wall St. Rank hold VKTX as of Q4 2018.

Ardsley Advisory Partners reported no remaining Viking Therapeutics position as of Q4 2018 after selling out during the quarter.
Ardsley Advisory Partners sold 10,000 Viking Therapeutics shares in Q4 2018, an estimated $174K.
Ardsley Advisory Partners first reported a position in Viking Therapeutics in Q2 2018 and held it in 2 quarters.
Ardsley Advisory Partners's Viking Therapeutics position peaked at $332K in Q2 2018.
168 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2018.

Based on Ardsley Advisory Partners's 13F filing for Q4 2018, filed 14 Feb 2019.